Abstract
WAYFINDER: A PHASE 3B, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TEZEPELUMAB IN REDUCING ORAL CORTICOSTERIODS (OCS) USE IN OCS-DEPENDENT PATIENTS WITH SEVERE ASTHMA
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have